Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6) (NCT02087566) | Clinical Trial Compass
CompletedNot Applicable
Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)
18 participantsStarted 2013-10
Plain-language summary
Renal failure patients were treated with linezolid (LZD) for proven or suspected infections by multiresistant Gram-positive cocci. The aim of this study is to determine if dose adjustment of LZD is needed as a function of renal impairment or not, especially that a significant component of LZD is eliminated unchanged in urine.
Who can participate
Age range22 Years – 50 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy subjects with normal renal function (CLcr ˃80 ml/min);
* Patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)
* Patients on long term HD with an ideal body weight of \>60 kg and a body mass index between 20 and 26 kg/m2
* Passed all the screening parameters
* Free of any drug exposure known to interfere with the pharmacokinetics or assay of linezolid for at least 10 days prior to the study
* Able to communicate effectively with study personnel, be literate, and able to give consent.
Exclusion Criteria:
Had a history of clinically significant organ dysfunction other than renal disease or those diseases associated with renal disease (as in case of acute RF or ESRD patients) Had physical examination or laboratory test results outside the inclusion such as; sitting systolic BP (SBP) of \>140 or \<100 mmHg, diastolic BP (DBP) \> 90 or \<60mm Hg (as in case of healthy volunteers and acute RF patients), or a pulse rate of \> 95 or \< 50 beats/min at screening; history of orthostatic hypotension; history of serious intolerance, allergy or sensitivity to linezolid ; history of blood dyscrasias; history of alcohol, smoking, or drug abuse; donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study; unable to tolerate vein puncture and multiple blood samplings; any surgical/medical condition that might alter the absorption, distribution, metabolism, excretion of linezolid ; or c…
What they're measuring
1
Tolerability
Timeframe: Participants will be followed for the duration of study, an expected average of 6 weeks.